Open AccessBCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells
Author(s) -
Ali Alhoshani,
Fahad O. Alatawi,
Fawaz E. Alanazi,
Ibraheem M. Attafi,
Asad Zeidan,
Abdelali Agouni,
Heba Gamal,
Licia Shamoon,
Sarah Khalaf,
Hesham M. Korashy
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s281519
Subject(s) - apoptosis , cancer research , cell cycle , cell cycle checkpoint , venetoclax , autophagy , cell growth , cyclin d1 , cancer , cancer cell , programmed cell death , breast cancer , g1 phase , chemistry , biology , medicine , leukemia , immunology , chronic lymphocytic leukemia , biochemistry
Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation.